Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4B | Q07343 | 5/20 | 0.44 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.39 |
| ▸ | USP2 | O75604 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | NAMPT | P43490 | 1/20 | 0.34 |
| ▸ | TACR1 | P25103 | 1/20 | 0.34 |
| ▸ | GLS | O94925 | 2/20 | 0.33 |
| ▸ | RECQL | P46063 | 1/20 | 0.32 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.32 |
| ▸ | FAAH | O00519 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31153913 | 0.90 | RECQL (0.38) | PDE4BUSP2SMN1; SMN2GLSRECQL | |
| SCHEMBL16909933 | 0.88 | NR1H2 (0.38) | PDE4BNR1H2USP2SMN1; SMN2NAMPT | |
| SCHEMBL16909934 | 0.88 | NR1H2 (0.38) | PDE4BNR1H2USP2SMN1; SMN2NAMPT | |
| SCHEMBL14805515 | 0.88 | NR1H2 (0.38) | PDE4BNR1H2USP2SMN1; SMN2NAMPT | |
| SCHEMBL1011802 | 0.88 | NR1H2 (0.41) | PDE4BNR1H2USP2SMN1; SMN2NAMPT | |
| SCHEMBL14805516 | 0.85 | PDE4B (0.43) | PDE4BNR1H2USP2SMN1; SMN2NAMPT | |
| SCHEMBL14801559 | 0.85 | PDE4B (0.43) | PDE4BNR1H2USP2SMN1; SMN2NAMPT | |
| SCHEMBL30455847 | 0.83 | NR1H2 (0.43) | PDE4BNR1H2USP2SMN1; SMN2NAMPT | |
| SCHEMBL2929277 | 0.82 | NR1H2 (0.49) | PDE4BNR1H2USP2SMN1; SMN2NAMPT | |
| SCHEMBL1018269 | 0.82 | NR1H2 (0.49) | PDE4BNR1H2USP2SMN1; SMN2NAMPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2272858-A2 | HCV inhibitors comprising beta amino acids and their uses | Novartis AG (CH) | 2011-01-12 | — | — | EP | disclosed |
| EP-2007787-A2 | HCV INHIBITORS COMPRISING BETA AMINO ACIDS AND THEIR USES | Novartis AG (CH) | 2008-12-31 | — | — | EP | disclosed |
| US-20080045530-A1 | Organic Compounds and Their Uses | BRANDL TRIXI | 2008-02-21 | — | — | US | disclosed |
| US-20080045530-A1 | Organic Compounds and Their Uses | BRANDL TRIXI | 2008-02-21 | — | — | US | disclosed |
| WO-2007121124-A2 | HCV INHIBITORS COMPRISING BETA AMINO ACIDS AND THEIR USES | NOVARTIS AG (CH) | 2007-10-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080045530-A1 | Organic Compounds and Their Uses | OAT, OTC, AOX1 | PDE4B 3578/4885NR1H2 531/4885USP2 2685/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.